Multiple Myeloma
American Society of Clinical Oncology, Cancer Care OntarioPublished: January 6, 2026
- Key Points
- Treatment
- Smoldering Multiple Myeloma
- Transplant Eligible – Evaluation of Eligibility
- Transplant Eligible – Initial Therapy
- Transplant Eligible – Conditioning and Transplant
- Transplant Eligible – Maintenance
- Transplant Eligible – Measurement of Response
- Transplant Ineligible – Therapy
- Transplant Ineligible – Goals of Therapy and Measurement of Response
- Relapsed/Refractory – Therapy
- Discussion Points Between Patients and Clinicians
- Figures and Algorithms
- Treatment of Newly Diagnosed Multiple Myeloma
- Treatment of Relapsed or Refractory Multiple Myeloma
Also Found In
You rely on Guideline Central for transparency
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.